Kazia Therapeutics Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

John Friend

Algemeen directeur

AU$1.6m

Totale compensatie

Percentage CEO-salaris	47.1%
Dienstverband CEO	1.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	2.3yrs

Recente managementupdates

Recent updates

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Jul 06

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Jun 15

Enrollment gets underway in Kazia's mid-stage lymphoma study

Jun 07

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Dec 10

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Dec 09

Kazia stock +22% on positive paxalisib data in glioblastoma

Nov 18

Analyse CEO-vergoeding

Hoe is John Friend's beloning veranderd ten opzichte van Kazia Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-AU$16m
Sep 30 2023	n/a	n/a	-AU$18m
Jun 30 2023	AU$2m	AU$743k	-AU$20m
Mar 31 2023	n/a	n/a	-AU$23m
Dec 31 2022	n/a	n/a	-AU$25m
Sep 30 2022	n/a	n/a	-AU$25m
Jun 30 2022	AU$1m	AU$430k	-AU$25m

Compensatie versus markt: De totale vergoeding ($USD 1.04M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 654.40K ).

Compensatie versus inkomsten: De vergoeding van John is gestegen terwijl het bedrijf verliesgevend is.

CEO

John Friend (54 yo)

1.5yrs

Tenure

AU$1,576,913

Compensatie

Dr. John Edwin Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Me...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
John Friend	CEO, MD & Director	1.5yrs	AU$1.58m	geen gegevens
Gabrielle Heaton	Principal Accounting Officer	7.7yrs	AU$297.48k	geen gegevens
Anna Sandham	Company Secretary	1.8yrs	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van KZIA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
John Friend	CEO, MD & Director	1.3yrs	AU$1.58m	geen gegevens
Robert Apple	Non-Executive Director	less than a year	geen gegevens	geen gegevens
Bryce Carmine	Independent Chairman	9.4yrs	AU$94.00k	geen gegevens
Patrick Wen	Member of Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
Steven Coffey	Independent Non-Executive Director	12yrs	AU$94.00k	geen gegevens
Ebru Davidson	Independent Non-Executive Director	1.4yrs	AU$7.12k	geen gegevens
Priscilla Brastianos	Member of Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
John de Groot	Member of Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens
Alan Olivero	Member of Scientific Advisory Board	2.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KZIA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.3 jaar), wat duidt op een nieuw bestuur.

Kazia Therapeutics Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

High number of new and inexperienced directors

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Recent updates

New minor risk - Financial data availability

Kazia Therapeutics Announces Presentation of Evt801 Clinical Data At 15 Biennial Ovarian Cancer Research Symposium

New major risk - Market cap size

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $10 million.

Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

New major risk - Share price stability

New major risk - Financial position

New minor risk - Financial data availability

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

High number of new and inexperienced directors

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Kazia Announces Receipt of Nasdaq Minimum Bid Notification

Kazia Therapeutics Announces the Publication of Pre-Clinical Data for Its Second Pipeline Asset, EVT801 in the Journal Cancer Research Communications

Kazia Therapeutics Limited Announces Publication of Positive Preclinical Data for Evt801

Kazia Therapeutics Limited's Paxalisib Demonstrates Positive Monotherapy Efficacy Signals in Preclinical Models of Melanoma

Kazia Therapeutics Limited Announces Expansion of PNOC Study into Australia

Kazia Therapeutics Limited, Annual General Meeting, Nov 16, 2022

Kazia Therapeutics Limited Presents Promising New Data from an Ongoing Phase I Clinical Trial of Paxalisib in Combination with Radiotherapy

Kazia Therapeutics Limited Provides Progress Update on GBM Agile Pivotal Study

Kazia Therapeutics Limited Launches New Scientific Advisory Board

Kazia Therapeutics Limited Launches New Scientific Advisory Board

United States Food and Drug Administration Awards Rare Pediatric Disease Designation to Kazia Therapeutics Limited's Paxalisib for AT/RT, Rare Form of Childhood Brain Cancer

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and EVT801 Clinical Programs

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Brain Metastases Advances to Expansion Stage in Breast Cancer Brain Metastases Cohort

Kazia Presents Positive Final Data from Phase II Study of Paxalisib in Newly Diagnosed Glioblastoma at ASCO Conference

Kazia to Present Final Data from Paxalisib Phase II Study in Glioblastoma At ASCO

Kazia Therapeutics Limited Announces Phase II Study of Paxalisib in Glioblastoma Achieves Final Completion

Kazia Presents Preclinical Data for Paxalisib At AACR

Kazia Therapeutics Limited Announces Phase II Clinical Study at Weill Cornell Medical Center Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet Enrolls First Patient

Kazia Therapeutics Limited Announces First Patient Enrolls in Phase II Clinical Study Investigating Paxalisib in Combination with Metformin and a Ketogenic Diet

Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0395 (Paxalisib) Issued by Thenational Medical Products Administration Under Collaboration with Kazia Therapeutics Limited

Kazia Releases Final Data from P2 Paxalisib Trial

Kazia Therapeutics Limited Provides Progress Update on Paxalisib and Evt801 Clinical Programs

Kazia Therapeutics Limited Announces Manufacturing Patents Granted for Paxalisib in Key Territories

Kazia Therapeutics Limited Launches New Paxalisib Phase II Clinical Trial

Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial

Kazia Therapeutics Limited Announces Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient

Enrollment gets underway in Kazia's mid-stage lymphoma study

Kazia Therapeutics Limited announced that it expects to receive AUD 5.2 million in funding from Simcere Pharmaceutical Group Limited

Kazia Licenses Cantrixil, to Oasmia Pharmacetical AB

Kazia Therapeutics Limited Announces GBM AGILE Pivotal Study Commences Recruitment to Paxalisib Arm

Kazia Therapeutics Limited to Collaborate with Pacific Pediatric Neuro-Oncology Consortium for New Paxalisib Combination Study in DIPG

Kazia Therapeutics Limited Announces Top-Line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

Kazia, Pacific Pediatric Neuro-Oncology collaborate for paxalisib combo study in type of brain cancer

Kazia Therapeutics -2% on cantrixil data in early-stage ovarian cancer study

Kazia Therapeutics Limited Presents Further Paxalisib Data At SNO, Confirming Earlier Positive Safety and Efficacy Signals in Glioblastoma

Kazia stock +22% on positive paxalisib data in glioblastoma

Kazia Therapeutics Limited Executes Agreement to Commence GBM Agile Pivotal Study

Kazia Therapeutics Limited Enters into Collaboration with Dana-Farber Cancer Institute in the United States to Investigate the Use of Kazia’S Investigational New Drug, Paxalisib

Kazia Therapeutics Limited Enter New Collaboration with Dana-Farber Cancer Institute